Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.

Testing Dispatch

Independent analysis puts a WXT tirzepatide lot at 96.4%, against 93.6% on the certificate

The report states the gradient, the wavelength and the integration threshold, which is more than most.

Two laboratories analysing vials from the same tirzepatide lot have returned figures 3.5 percentage points apart. PeptideMeter reported 96.4%; Medutest reported a lower number on a shallower gradient with a tighter integration threshold. Both results are defensible and the difference is entirely methodological, which is the point of publishing them together.

Content by elemental nitrogen determination returned 93% of the labelled nominal mass, which on a 10 mg vial corresponds to roughly 7.54 mg of peptide rather than the labelled figure. The remainder is accounted for by counter-ion, residual water and residual solvent, none of which is visible chromatographically.

Batch variance rather than vendor quality is the recurring finding of this programme. Across the 15 determinations the Journal has commissioned to date, within-vendor spread has been wider than between-vendor spread for two thirds of the companies tracked, which is an argument against rating any supplier on a single number.

"Ask for the suitability summary before you argue about the percentage," said Dr Emiko Tanabe, mass spectrometrist. "If the tailing factor and the replicate precision are outside limits, you are arguing about arithmetic performed on an unfit separation."

WXT’s dossier has been updated with this determination and with the company’s response to it. The dossier’s ordering box records the lead times, the minimum quantities and what a buyer should ask for at the point of order.

Related coverage